• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Monarch Medical Technologies Appoints Raymie McFarland as President and CEO

Article

The highly respected healthcare industry veteran will bring his signature team building skills, track record of double-digit revenue growth and subject matter expertise in diabetes.

Monarch Medical Technologies, maker of the EndoTool® Glucose Management System, recently announced Raymie McFarland will serve as its new President and Chief Executive Officer. McFarland has been deeply entrenched in the diabetes technology, consultancy and pharmaceutical sectors of the healthcare industry for more than 20 years. Among thought leaders and colleagues, he is known as much for his subject matter expertise, creativity and resourcefulness as he is for his strategic foresight and charisma.

Brian Duffy and Christophe Mallard, two of Monarch Medical Technologies’ Board members, will relinquish their respective roles as Interim Chief Executive Officer and Interim President, turning over day-to-day management of the company to McFarland.

“We are thrilled to welcome Raymie to the Monarch family," Duffy says. "He is, as many people will attest, a one-of-a-kind talent. His in-depth knowledge of diabetes and, more specifically, of glycemic management and insulin therapies, is extraordinary.”

Mallard adds, "Raymie’s track record of success in cultivating customer relationships, building high-performing teams, engaging key opinion leaders and generating revenue is unimpeachable. He has a keen ability to articulate the benefits of innovative tools, technologies and processes to clinicians, administrators and senior executives alike. He is also highly experienced in conducting scientific research and measuring both clinical efficacy and financial ROI.”

McFarland spent the last nine years with Glytec, most recently as Chief Innovation and Outcomes Officer. During his tenure, McFarland added more than 200 sites to the company’s customer roster, built a Quality Initiatives division from the ground up and directed more than 85 diabetes-related research studies. Prior to Glytec, McFarland was president of Mantra Healthcare Solutions, a glycemic management consultancy he co-founded.

Earlier in his career, McFarland worked for pharmaceutical giant, Sanofi, where he developed and facilitated multiple programs aimed at improving the care of persons with diabetes.

McFarland holds certifications from CMS Readmissions Programming, Telehealth Remote Monitoring, Quality Lean Processing, Six Sigma and Quality Institute.

“Although there is no playbook for leadership in the face of a pandemic, we have the utmost confidence that Raymie’s strong business acumen and customer-first mindset is exactly what Monarch needs," says Duffy. "He is well positioned to address the challenges of our nation’s healthcare providers and persons with diabetes.”

© 2024 MJH Life Sciences

All rights reserved.